BioTuesdays
iBio Inc.

iBio initiates second COVID-19 vaccine program

iBio (NYSE AMERICAN:IBIO) initiated preclinical immunization studies for its second COVID-19 vaccine platform with the potential for rapid manufacturing scale-up at its FastPharming System. The new subunit vaccine, IBIO...

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

Maxim ups Co-Diagnostics to buy; PT $30

Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...

Neuronetics Logo

WB cuts Neuronetics to market perform

William Blair downgraded Neuronetics (NASDAQ:STIM) to “market perform,” citing added uncertainty from COVID-19 headwinds and a commercial restructuring. The stock was quoted at $2.20, down 16 cents, in afternoon trading...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.